Assenagon Asset Management S.A. reduced its stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) by 94.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 10,531 shares of the medical instruments supplier’s stock after selling 171,862 shares during the period. Assenagon Asset Management S.A.’s holdings in Glaukos were worth $1,134,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Glaukos by 9.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 122 shares during the period. Larson Financial Group LLC increased its holdings in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares in the last quarter. CWM LLC raised its stake in shares of Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 143 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after purchasing an additional 144 shares during the period. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Glaukos by 4.3% in the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 145 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.
Insider Activity
In related news, Director Leana Wen sold 1,700 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the completion of the sale, the director directly owned 19,739 shares in the company, valued at approximately $2,829,585.65. This trade represents a 7.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 19,573 shares of Glaukos stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.54, for a total value of $2,809,508.42. Following the transaction, the chief operating officer owned 73,419 shares of the company’s stock, valued at $10,538,563.26. The trade was a 21.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,273 shares of company stock valued at $5,832,003 in the last 90 days. 5.90% of the stock is owned by company insiders.
Glaukos Stock Performance
Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter last year, the company posted ($0.22) earnings per share. The company’s revenue for the quarter was up 41.2% compared to the same quarter last year. As a group, research analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the company. Needham & Company LLC upped their price objective on Glaukos from $136.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Wells Fargo & Company boosted their target price on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Stifel Nicolaus set a $170.00 price target on Glaukos in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.17.
Read Our Latest Report on Glaukos
Glaukos Profile
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
- Five stocks we like better than Glaukos
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
